APA

Blanken M., Rovers M., Sanders E. & Bont L. (20130304). Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. : Contemporary clinical trials.

Chicago

Blanken Maarten, Rovers Maroeska, Sanders Elisabeth and Bont Louis. 20130304. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. : Contemporary clinical trials.

Harvard

Blanken M., Rovers M., Sanders E. and Bont L. (20130304). Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. : Contemporary clinical trials.

MLA

Blanken Maarten, Rovers Maroeska, Sanders Elisabeth and Bont Louis. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. : Contemporary clinical trials. 20130304.